Pro Medicus (PME) investor relations material

Executive summary

• Achieved record financial results with revenue up nearly 32% and profit after tax up 39–40% year-over-year.

• Secured seven new contracts totaling $520M, renewed two large contracts worth $130M, and completed seven implementations.

• Expanded product portfolio with launches in cardiology, digital pathology, and AI initiatives, forming a strong base for future growth.

• Maintained 100% renewal rate, with all renewals at higher price points and longer terms.

• North American footprint and pipeline continue to grow, with 11 of the top 20 US hospitals using the platform.

Financial highlights

• Revenue reached $213.0M, up just under 32% year-over-year; profit after tax was $115.2M, up about 40%.

• Underlying EBIT grew 40–40.5% to $157.7M, with margins improving to 74%.

• Retained earnings increased by 36%; cash and investments totaled $210.7M, up 35.5%, with no debt.

• Fully franked dividend of $0.30 per share for the half, up 37.5%.

• Recurring transaction revenue and professional services revenue both contributed to growth.

Outlook and guidance

• Strong base for continued growth in FY26 and beyond, with a robust and refreshed sales pipeline.

• Forward revenue minimums increased to $948M over five years, with upside potential as client volumes grow.

• Digital pathology to be released this year; further AI commercialization pending FDA clearance.

• Cloud deployment and AI integration expected to drive future growth and competitive advantage.

• Operating cost growth expected to remain consistent with prior years, mainly from new headcount.